Anthropic is launching an internal drug discovery program with a focus on neglected diseases that traditional pharmaceutical companies would not consider commercially attractive, CNBC reported June 30 ...

Anthropic will start a drug discovery program focused on "neglected" diseases. The artificial intelligence company announced the effort alongside the announcement of Claude Science, a product designed ...

Many venture capitalists contend that AI is set to turbocharge drug discovery. Jim Healy isn’t one of them. Healy is managing partner of Sofinnova Investments, which formed in 1976 and helped birth ...

Developing new medicines can require thousands of chemistry experiments to identify the right recipe for a safe, effective and ideally affordable drug. The process is slow and labor-intensive, and ...

WEST LAFAYETTE, Ind. — Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and ...

STOCKHOLM & LUND, Sweden--(BUSINESS WIRE)--Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Republicans hope a splintered Democratic field could produce a weaker ...

The path forward in drug discovery isn’t always easy – and sometimes it requires creative vision or new technology to help drive progress. In this spotlight, Nature looks at the challenges associated ...

The main super PAC tied to the influential American Israel Public Affairs Committee released its first ads backing Ms. Stevens, a moderate congresswoman locked in a tight three-way primary. By ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Rep. Sarah Stevens resigned effective June 16 to focus on her 2026 Supreme Court campaign. Stevens, a Republican, is running to ...

The biotech industry is in the midst of an artificial intelligence (AI) investment surge, with companies pouring billions into the promise of faster, smarter drug discovery. As leaders in R&D, we have ...